Diametric Capital LP Buys 7,244 Shares of INmune Bio, Inc. (NASDAQ:INMB)

Diametric Capital LP raised its stake in shares of INmune Bio, Inc. (NASDAQ:INMB) by 24.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 36,699 shares of the company’s stock after purchasing an additional 7,244 shares during the quarter. Diametric Capital LP owned 0.17% of INmune Bio worth $171,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in INmune Bio during the fourth quarter worth $2,221,000. State Street Corp lifted its holdings in shares of INmune Bio by 35.1% during the 3rd quarter. State Street Corp now owns 226,428 shares of the company’s stock worth $1,220,000 after acquiring an additional 58,838 shares during the period. XTX Topco Ltd acquired a new stake in shares of INmune Bio during the 3rd quarter valued at about $249,000. Westside Investment Management Inc. increased its stake in INmune Bio by 57.3% in the third quarter. Westside Investment Management Inc. now owns 71,315 shares of the company’s stock valued at $384,000 after acquiring an additional 25,975 shares during the period. Finally, Barclays PLC raised its position in INmune Bio by 601.9% in the third quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after purchasing an additional 24,906 shares in the last quarter. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Stock Performance

Shares of INMB opened at $8.07 on Thursday. The company has a market cap of $214.59 million, a price-to-earnings ratio of -3.70 and a beta of 1.93. The stock has a fifty day moving average price of $8.46 and a two-hundred day moving average price of $6.42. INmune Bio, Inc. has a 52-week low of $4.32 and a 52-week high of $12.72.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.14. As a group, research analysts predict that INmune Bio, Inc. will post -2.24 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on INMB. Maxim Group upped their price objective on INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Scotiabank upped their price target on INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Tuesday, February 11th. RODMAN&RENSHAW raised INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on shares of INmune Bio in a report on Tuesday, January 28th. They issued a “buy” rating and a $23.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.